title: [Practical prevention and treatment of cardiovascular diseases in patients with diabetes mellitus type 2 in an endocrinological department].
abstract: OBJECTIVE
  To analyse retrospectively quality of medical correction of modified risk factors (RF) and treatment of cardiovascular diseases (CVD) in patients with diabetes mellitus type (DM) 2 admitted to specialized endocrinological departments.
  
  
  METHODS
  Analysis of medication policy of CVD RF was made retrospectively for 250 patients treated in endocrinological departments of Moscow hospital in 2003.
  
  
  RESULTS
  Arterial hypertension, coronary heart disease were diagnosed in 93.2 and 87.2% examinees. History of myocardial infarction and brain stroke was in 8.4 and 6% patients. Statins were prescribed in 2.4% cases. Examination for dyslipidemia was not satisfactory. ACE inhibitors were prescribed in 71.2% patients. Aspirin was prescribed (18%) primarily by the cardiologist.
  
  
  CONCLUSIONS
  Quality of medical prophylaxis of CVD RF in DM type 2 patients in the departments does not satisfy modern clinical recommendations.
authors.forename: L V
authors.initials: LV
authors.lastname: Daurbekova
authors.forename: V A
authors.initials: VA
authors.lastname: Orlov
authors.forename: S R
authors.initials: SR
authors.lastname: Giliarevskiĭ
authors.forename: E S
authors.initials: ES
authors.lastname: Abirova
authors.forename: L I
authors.initials: LI
authors.lastname: Murzabekova
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004704:Endocrinology; D006748:Hospital Departments; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin